Why Citius Pharmaceuticals (CTXR) Stock Is Down 15%

Citius Pharmaceuticals Inc CTXR shares are trading lower by 14.2% to $3.75 during Wednesday’s session after the company announced a $3 million registered direct offering priced at-the-market under Nasdaq rules.

The company will issue 743,496 shares of common stock and warrants to purchase the same number of shares at a combined price of $4.035 per share and warrant. The warrants, exercisable at $3.91 per share, will become active immediately upon issuance and remain valid for five years.

The offering, led by H.C. Wainwright & Co. as the exclusive placement agent, is expected to close around January 8, pending customary conditions.

Proceeds will support corporate purposes, including clinical development, preclinical research, working capital and capital expenditures.

Read Also: US Private Businesses Add 122,000 Jobs In December: ‘Slowdown In Both Hiring And Pay Gains’

Should I Sell My CTXR Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Citius Pharmaceuticals stock currently has an RSI of 86.04, indicating overbought conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

CTXR has a 52-week high of $26.75 and a 52-week low of $2.44.